Calcium-dependent potentiation of the pro-inflammatory functions of human neutrophils by tigecycline in vitro

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 1, 2012, Pages 130-137

  Cockeran, Riana ^a   Mutepe, Ndiafhi D ^a   Theron, Annette J ^a   Tintinger, Gregory R ^a   Steel, Helen C ^a   Stivaktas, Paraskevi ^a   Richards, Guy A ^b   Feldman, Charles ^b   Anderson, Ronald ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Calcium ionophore; Doxycycline; Innate immunity; Minocycline; Oxidant scavenger; Tetracycline

Indexed keywords

CALCIUM; ELASTASE; FORMYLMETHIONYLLEUCYLPHENYLALANINE; GELATINASE B; IONOPHORE; MYELOPEROXIDASE; NEUTROPHIL COLLAGENASE; REACTIVE OXYGEN METABOLITE; TIGECYCLINE; DRUG DERIVATIVE; IMMUNOLOGIC FACTOR; MINOCYCLINE; N FORMYLMETHIONYL LEUCYL PHENYLALANYL LYSINE; N-FORMYLMETHIONYL-LEUCYL-PHENYLALANYL-LYSINE;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IODINATION; LEUKOCYTE ACTIVATION; LEUKOCYTE FUNCTION; NEUTROPHIL; NORMAL HUMAN; OXYGEN CONSUMPTION; RADIOMETRY; SPECTROFLUOROMETRY; CELL CULTURE; CHEMISTRY; CYTOSOL; DRUG EFFECT; HUMAN EXPERIMENT; IMMUNOLOGY; METABOLISM;

ADULT; CALCIUM; CELLS, CULTURED; CYTOSOL; HUMAN EXPERIMENTATION; HUMANS; IMMUNOLOGIC FACTORS; MINOCYCLINE; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; NEUTROPHILS;

EID: 84859177869     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr441     Document Type: Article

References (49)

1. Rubinstein E, Vaughan D. Tigecycline: a novel glycylcycline. Drugs 2005; 65: 1317-1336.
2. Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005; 41 Suppl 5: S303-S314.
3. Zhanel GG, Karlowsky JA, Rubinstein E et al. Tigecycline: a novel glycylcycline antibiotic. Expert Rev Anti Infect Ther 2006; 4: 9-25.
4. Ong CT, Babalola CP, Nightingale CH et al. Penetration, efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs). J Antimicrob Chemother 2005; 56: 498-501.
5. Pollock JD, Williams DA, Gifford MA et al. Mouse model of X-linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production. Nat Genet 1995; 9: 202-209.
6. Graves SF, Kobayashi SD, DeLeo FR. Community-associated methicillin-resistant Staphylococcus aureus immune evasion and virulence. J Mol Med 2010; 88: 109-114.
7. Anderson R, Tintinger G, Cockeran R et al. Beneficial and harmful interactions of antibiotics with microbial pathogens and the host immune system. Pharmaceuticals 2010; 3: 1694-1710.
8. Nelson ML. Chemical and biological dynamics of tetracyclines. Adv Dent Res 1998; 12: 5-11.
9. Rodvold KA, Gotfried MH, Cwik M et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006; 58: 1221-1229.
10. Cunha BA. Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis. J Clin Microbiol 2009; 47: 1613.
11. Conte JE Jr, Golden JA, Kelly MG et al. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 2005; 25: 523-529.
12. Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 3340-3350.
13. Anderson R, Goolam Mahomed A. Calcium efflux and influx in f-met-leu-phe (fMLP)-activated human neutrophils are chronologically distinct events. Clin Exp Immunol 1997; 110: 132-138.
14. Halliwell B, Wasil M. Tetracyclines as antioxidants in rheumatoid arthritis: scavenging of hypochlorous acid. J Rheumatol 1988; 15: 530.
15. Wasil M, Halliwell B, Moorhouse CP. Scavenging of hypochlorous acid by tetracycline, rifampicin and some other antibiotics: a possible antioxidant action of rifampicin and tetracycline? Biochem Pharmacol 1988; 37: 775-778.
16. Sorsa T, Ramamurthy NS, Vernillo AT et al. Functional sites of chemically modified tetracyclines: inhibition of the oxidative activation of human neutrophil and chicken osteoclast pro-matrix metalloproteinases. J Rheumatol 1998; 25: 975-982.
17. Aronoff DM, Lewis C, Serezani CH et al. E-prostanoid 3 receptor deletion improves pulmonary host defense and protects mice from death in severe Streptococcus pneumoniae infection. J Immunol 2009; 183: 2642-2649.
18. Stables MJ, Newton J, Ayoub SS et al. Priming innate immune responses to infection by cyclooxygenase inhibition kills antibioticsusceptible and -resistant bacteria. Blood 2010; 116: 2950-2959.
19. Tasaka S, Amaya F, Hashimoto S et al. Roles of oxidants and redox signaling in the pathogenesis of acute respiratory distress syndrome. Antioxid Redox Signal 2008; 10: 739-753.
20. + flux. Nature 2002; 416: 291-297.
21. Young RE, Voisin MB, Wang S et al. Role of neutrophil elastase in LTB4-induced neutrophil transmigration in vivo assessed with a specific inhibitor and neutrophil elastase deficient mice. Br J Pharmacol 2007; 151: 628-637.
22. Khatwa UA, Kleibrink BE, Shapiro SD et al. MMP-8 promotes polymorphonuclear cell migration through collagen barriers in obliterative bronchiolitis. J Leukoc Biol 2010; 87: 69-77.
23. Renckens R, Roelofs JJ, Florquin S et al. Matrix metalloproteinase-9 deficiency impairs host defense against abdominal sepsis. J Immunol 2006; 176: 3735-3741.
24. Leppert D, Leib SL, Grygar C et al. Matrix metalloproteinase (MMP)-8 and MMP-9 in cerebrospinal fluid during bacterial meningitis: association with blood-brain barrier damage and neurological sequelae. Clin Infect Dis 2000; 31: 80-84.
25. Meli DN, Christen S, Leib SL. Matrix metalloproteinase-9 in pneumococcal meningitis: activation via an oxidative pathway. J Infect Dis 2003; 187: 1411-1415.
26. α. J Neurochem 2007; 102: 900-912.
27. Hartog CM, Wermelt JA, Sommerfeld CO et al. Pulmonary matrix metalloproteinase excess in hospital-acquired pneumonia. Am J Respir Crit Care Med 2003; 167: 593-598.
28. Kim JH, Suk MH, Yoon DW et al. Inhibition of matrix metalloproteinase-9 prevents neutrophilic inflammation in ventilator-induced lung injury. Am J Physiol Lung Cell Mol Physiol 2006; 291: L580-L587.
29. Schaaf B, Liebau C, Kurowski V et al. Hospital acquired pneumonia with high-risk bacteria is associated with increased pulmonary matrix metalloproteinase activity. BMC Pulm Med 2008; 8: 12.
30. Finkel TH, Pabst MJ, Suzuki H et al. Priming of neutrophils and macrophages for enhanced release of superoxide anion by the calcium ionophore ionomycin. Implications for regulation of the respiratory burst. J Biol Chem 1987; 262: 12589-12596.
31. 2+ influx and stimulation of exocytosis in HL-60 granulocytes. J Biol Chem 1997; 272: 28360-28367.
32. Bleasdale JE, Thakur NR, Gremban RS et al. Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils. J Pharmacol Exp Ther 1990; 255: 756-768.
33. Sadowski T, Steinmeyer J. Effects of tetracyclines on the production of matrix metalloproteinases and plasminogen activators as well as their natural inhibitors, tissue inhibitor of metalloproteinases-1 and plasminogen activator inhibitor-1. Inflamm Res 2001; 50: 175-182.
34. Fiotti N, Altamura N, Moretti M et al. Short-term effects of doxycycline on matrix metalloproteinases 2 and 9. Cardiovasc Drugs Ther 2009; 23: 153-159.
35. Lindeman JH, Abdul-Hussien H, van Bockel JH et al. Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with abdominal aneurysm: doxycycline selectively depletes aortic wall neutrophils and cytotoxic T cells. Circulation 2009; 119: 2209-2216.
36. Sochor M, Richter S, Schmidt A et al. Inhibition of matrix metalloproteinase-9 with doxycycline reduces pancreatitis-associated lung injury. Digestion 2009; 80: 65-73.
37. Abdul-Hussien H, Hanemaaijer R, Verheijen JH et al. Doxycycline therapy for abdominal aneurysm: improved proteolytic balance through reduced neutrophil content. J Vasc Surg 2009; 49: 741-749.
38. Huang TY, Chu PC, Lin YL et al. Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases. Toxicol Appl Pharmacol 2009; 237: 69-82.
39. Kaushik V, Beduya D, Kalampokis I et al. Tetracyclines tigecycline and doxycycline inhibit LPS-induced nitric oxide production by RAW 264.7 murine macrophages. J Immunol 2007; 178 Suppl: S200-1, Abstract 101.3.
40. Choi SH, Lee DY, Chung ES et al. Inhibition of thrombin-induced microglial activation and NADPH oxidase by minocycline protects dopaminergic neurons in the substantia nigra in vivo. J Neurochem 2005; 95: 1755-1765.
41. Dunston CR, Griffiths HR, Lambert PA et al. Proteomic analysis of the anti-inflammatory action of minocycline. Proteomics 2011; 11: 42-51.
42. Baumann MH, Heinrich K, Sahn SA et al. Pleural macrophages differentially alter mesothelial cell growth and collagen production.Inflammation 1993; 17: 1-12.
43. Miller EJ, Kajikawa O, Pueblitz S et al. Chemokine involvement in tetracycline-induced pleuritis. Eur Respir J 1999; 14: 1387-1393.
44. Kloppenburg M, Brinkman BM, de Rooij-Dijk HH et al. The tetracycline derivative minocycline differentially affects cytokine production by monocytes and T lymphocytes. Antimicrob Agents Chemother 1996; 40:934-940.
45. Hollborn M, Wiedemann P, Bringmann A et al. Chemotactic and cytotoxic effects of minocycline on human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 2010; 51: 2721-2729.
46. Potter EG, Cheng Y, Natale JE. Deleterious effects of minocycline after in vivo target deprivation of thalamocortical neurons in the immature,metallothionein-deficient mouse brain. J Neurosci Res 2009; 87:1356-1368.
47. Cai Y, Wang R, Liang B et al. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for the treatment of infectious disease. Antimicrob Agents Chemother 2010; 55: 1162-1172.
48. Townsend ML, Pound MW, Drew RH. Potential role of tigecycline in the treatment of community-acquired bacterial pneumonia. Infect Drug Resist 2011; 4: 77-86.
49. Freire AT, Melnyk V, Kim MJ et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.Diagn Microbiol Infect Dis 2010; 68: 140-151.